A rare variant in TREM2 (p.R47H, rs75932628) was recently reported to increase the risk of Alzheimer's disease (AD) and, subsequently, other neurodegenerative diseases, i.e. frontotemporal lobar degeneration (FTLD), amyotrophic lateral sclerosis (ALS), and Parkinson's disease (PD). 4 key findings →
Design: meta-analysis
Participants: 828
Evidence: high
Full summary, score breakdown and related studies →
Original source
Free full text
Amyloid-beta 42 (Aβ42) and phosphorylated tau (pTau) levels in cerebrospinal fluid (CSF) reflect core features of the pathogenesis of Alzheimer's disease (AD) more directly than clinical diagnosis. 2 key findings →
Participants: 8,074
Evidence: low
Full summary, score breakdown and related studies →
Original source
Free full text
72/100
✓ Peer-reviewed
alzhub usefulness score 72 out of 100.
·
Neurology
·
1999-12-01
The diabetes attributable risk for dementia of 8.8% suggests that diabetes may have contributed to the clinical syndrome in a substantial proportion of all dementia patients. 2 key findings →
Design: cohort study
Participants: 126
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Full text may need a subscription
The average life expectancy has increased substantially in the past few decades in most industrialized countries; however, not all of the increased life expectancy is being spent in optimal health, especially among individuals with low socioeconomic status. 4 key findings →
Design: cohort study
Participants: 135
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Free full text
Vascular cognitive impairment is an umbrella term for cognitive dysfunction associated with and presumed to be caused by vascular brain damage. 2 key findings →
Participants: 10,515
Evidence: low
Full summary, score breakdown and related studies →
Original source
Free full text
Vascular risk factors, such as type 2 diabetes, hypertension, obesity and dyslipidaemia often co-occur. 3 key findings →
Design: longitudinal study
Participants: 14
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Full text may need a subscription
65/100
✓ Peer-reviewed
alzhub usefulness score 65 out of 100.
·
Diabetes Care
·
2025-09-19
After a median follow-up time of 14.3 (7.9-20.0) years, dementia was recorded in 530 (1.2%) individuals with type 1 diabetes and 1,867 (0.9%) age-, sex-, and county-matched control individuals (mean baseline age 33.0 [14.0] years). 4 key findings →
Design: cohort study
Participants: 43,440
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Free full text
64/100
✓ Peer-reviewed
alzhub usefulness score 64 out of 100.
·
Nature genetics
·
2009-09-06
We conducted a genome-wide association study among 2,323 individuals with sporadic amyotrophic lateral sclerosis (ALS) and 9,013 control subjects and evaluated all SNPs with P < 1.0 x 10(-4) in a second, independent cohort of 2,532 affected individuals and 5,940 controls. 1 key finding →
Participants: 2,323
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Free full text
64/100
✓ Peer-reviewed
alzhub usefulness score 64 out of 100.
·
BMC medicine
·
2021-05-19
Sex differences in major cardiovascular risk factors for incident (fatal or non-fatal) all-cause dementia were assessed in the UK Biobank. 4 key findings →
Participants: 502,226
Evidence: low
Full summary, score breakdown and related studies →
Original source
Free full text
Eight candidate predictors entered the prediction model: bulbar versus non-bulbar onset (univariable hazard ratio [HR] 1·71, 95% CI 1·63-1·79), age at onset (1·03, 1·03-1·03), definite versus probable or possible ALS (1·47, 1·39-1·55), diagnostic delay (0·52, 0·51-0·53), forced vital capacity (HR 0·99, 0·99-0·99), progression rate (6·33, 5·92-6·76), frontotemporal dementia (1·34, 1·20-1·50), and presence of a C9orf72 repeat expansion (1·45, 1·31-1·61), all p Interpretation We have developed an externally validated model to predict survival without tracheostomy and non-invasive ventilation for more than 23 h per day in European patients with ALS. 1 key finding →
Participants: 1,936
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Free full text
Out of 929 patients, 184 (20%) experienced POD. 5 key findings →
Design: cohort study
Participants: 929
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Free full text
61/100
✓ Peer-reviewed
alzhub usefulness score 61 out of 100.
·
PLoS medicine
·
2022-04-05
Women's reproductive factors have been associated with the risk of dementia; however, these findings remain uncertain. 4 key findings →
Participants: 273,240
Evidence: low
Full summary, score breakdown and related studies →
Original source
Free full text
In this large cohort of older adults, long-term PM2.5 exposure was associated with increased dementia incidence. 3 key findings →
Participants: 541
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Free full text
60/100
✓ Peer-reviewed
alzhub usefulness score 60 out of 100.
·
Nature medicine
·
2018-02-05
An intronic GGGGCC repeat expansion in C9ORF72 is the most common cause of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), but the pathogenic mechanism of this repeat remains unclear. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies →
Original source
Free full text
Only 11 putative risk factors for delirium are supported by either strong or moderate level of evidence. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies →
Original source
Free full text
The prevalence and the degree of cerebral white matter lesions increased with age. 2 key findings →
Participants: 1,077
Evidence: low
Full summary, score breakdown and related studies →
Original source
Free full text
Amyotrophic lateral sclerosis is characterised by the progressive loss of motor neurons in the brain and spinal cord. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies →
Original source
Free full text
Atherosclerotic lesions are known for their cellular heterogeneity, yet the molecular complexity within the cells of human plaques has not been fully assessed. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies →
Original source
Free full text
White matter hyperintensities (WMHs) are frequently seen on brain magnetic resonance imaging scans of older people. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies →
Original source
Free full text
Long-term exposure to PM 2.5 , NO 2 , and/or BC in Denmark were associated with mortality beyond cardiorespiratory diseases, including diabetes, dementia, psychiatric disorders, asthma, and ALRI. 5 key findings →
Participants: 803,881
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Free full text
57/100
✓ Peer-reviewed
alzhub usefulness score 57 out of 100.
·
Nature aging
·
2022-09-20
Microglia and complement can mediate neurodegeneration in Alzheimer's disease (AD). 4 key findings →
Evidence: low
Full summary, score breakdown and related studies →
Original source
Free full text
57/100
✓ Peer-reviewed
alzhub usefulness score 57 out of 100.
·
Neurology
·
2025-06-11
The study included 356,173 participants (median age 56 years; 53.69% female). 5 key findings →
Participants: 356,173
Evidence: low
Full summary, score breakdown and related studies →
Original source
Free full text
55/100
✓ Peer-reviewed
alzhub usefulness score 55 out of 100.
·
Diabetes care
·
2024-09-01
Participants were 60 (range 44-74) years old with 38 (30-51) years' T1D duration. 3 key findings →
Participants: 373
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Free full text
Sex or gender differences in the risk of Alzheimer's disease and related dementias (ADRD) differ by world region, suggesting that there are potentially modifiable risk factors for intervention. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies →
Original source
Free full text
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease that results in progressive loss of bulbar and limb function. 2 key findings →
Participants: 100,000
Evidence: low
Full summary, score breakdown and related studies →
Original source
Full text may need a subscription
How the 0–100 score works — and why some entries are capped
This is alzhub's own score. It is not an official metric, not an impact factor,
and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a
scientist can tell a landmark trial from a conference abstract without having to already know the
difference. Every point comes from one of 20 components, all of them printed on the study itself,
so you can disagree with our arithmetic rather than having to trust the total.
- Journal tier up to 10 pts
- Journal's citation record up to 4 pts
- Study design up to 12 pts
- Strength of evidence up to 5 pts
- Peer-review validation up to 10 pts
- How recent up to 5 pts
- Sample size up to 4 pts
- Effect reported up to 3 pts
- Studied in people up to 3 pts
- Randomised / blinded up to 2 pts
- Times cited up to 7 pts
- Citations per year up to 5 pts
- Impact for its field and year up to 6 pts
- Cited by studies here up to 6 pts
- Still being cited up to 4 pts
- Senior author's track record up to 4 pts
- Institution's track record up to 3 pts
- Multi-centre collaboration up to 3 pts
- Indexed in PubMed up to 2 pts
- Free to read up to 2 pts
Journals are placed in ordered tiers, never given a numeric impact factor — we
could not verify current impact factors from a source we control, and an invented one would be
worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science,
Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed
journal. A separate part scores how much the journal's own papers are cited, which tells the
tier-3 journals apart.
Two rules we don't bend. First, we never fill in a
missing value: if a record does not state a sample size or a design, that component scores
zero, and if we simply have no data for a part, such as a citation count, that part is left out and
the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed
article is capped at 16/100 and carries a warning chip — so a conference abstract or
a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not
work — above an early positive finding. Someone deciding whether to buy a supplement is served by
that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is
reproducible: the same file always yields the same numbers.
See the whole rubric drawn out →
— four charts covering all 27,380 studies: how the scores are spread and where the cap
bites, which of the 20 components the library is strong and weak on, which subjects rest on
stronger evidence, and what kinds of study each subject is actually built from.